EA202191658A1 - Антитела против фактора c2b комплемента человека и способы применения - Google Patents

Антитела против фактора c2b комплемента человека и способы применения

Info

Publication number
EA202191658A1
EA202191658A1 EA202191658A EA202191658A EA202191658A1 EA 202191658 A1 EA202191658 A1 EA 202191658A1 EA 202191658 A EA202191658 A EA 202191658A EA 202191658 A EA202191658 A EA 202191658A EA 202191658 A1 EA202191658 A1 EA 202191658A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
antibodies
binding fragments
inhibit
methods
Prior art date
Application number
EA202191658A
Other languages
English (en)
Inventor
Кристоф Бланхетот
Ханс Де Хард
Original Assignee
Ардженкс Бвба
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ардженкс Бвба filed Critical Ардженкс Бвба
Publication of EA202191658A1 publication Critical patent/EA202191658A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Предложены антитела и их антигенсвязывающие фрагменты, которые специфически связываются с фактором C2 комплемента человека и способны ингибировать активацию классического и лектинового путей системы комплемента. Антитела и антигенсвязывающий фрагмент демонстрируют улучшенную технологичность, фармакокинетику и широкий охват антигенов. Также предложены фармацевтические композиции, содержащие антитела и антигенсвязывающие фрагменты, нуклеиновые кислоты и векторы, кодирующие антитела и антигенсвязывающие фрагменты, клетки-хозяева, содержащие нуклеиновые кислоты или векторы, и способы получения и применения антител и антигенсвязывающих фрагментов. Антитела и антигенсвязывающие фрагменты можно использовать для ингибирования классического пути активации комплемента у пациента, например человека. Антитела и антигенсвязывающие фрагменты также можно использовать для ингибирования лектинового пути активации комплемента у пациента, например человека.
EA202191658A 2018-12-13 2019-12-13 Антитела против фактора c2b комплемента человека и способы применения EA202191658A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779102P 2018-12-13 2018-12-13
PCT/IB2019/060802 WO2020121282A1 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor c2b and methods of use

Publications (1)

Publication Number Publication Date
EA202191658A1 true EA202191658A1 (ru) 2021-11-03

Family

ID=69143627

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191658A EA202191658A1 (ru) 2018-12-13 2019-12-13 Антитела против фактора c2b комплемента человека и способы применения

Country Status (13)

Country Link
US (4) US11161900B2 (ru)
EP (2) EP4375297A2 (ru)
JP (2) JP7110491B2 (ru)
KR (1) KR20210100688A (ru)
CN (1) CN113260375A (ru)
AU (2) AU2019397614B2 (ru)
BR (1) BR112021011107A2 (ru)
CA (1) CA3119655A1 (ru)
EA (1) EA202191658A1 (ru)
IL (1) IL283916A (ru)
MX (1) MX2021006864A (ru)
SG (1) SG11202105195PA (ru)
WO (1) WO2020121282A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119655A1 (en) 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
EP2288382B1 (en) * 2008-05-05 2018-08-29 NovImmune SA Anti- il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
EP2585110A4 (en) * 2010-06-22 2014-01-22 Univ Colorado Regents ANTIBODIES AGAINST THE C3D FRAGMENT OF COMPONENT COMPONENT 3
ME03755B (me) * 2011-05-04 2021-04-20 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
HUE047375T2 (hu) 2011-09-07 2020-04-28 Univ Pennsylvania Javított farmakokinetikai tulajdonságokkal rendelkezõ compstatin analógok
PT2914291T (pt) * 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
WO2014096958A1 (en) 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
US20160090425A1 (en) 2013-05-15 2016-03-31 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
DK2999714T3 (da) * 2013-05-23 2020-06-02 Broteio Pharma B V Bindingsmolekyler som binder til human komplementfaktor C2 og anvendelser deraf
CA2859114A1 (en) 2013-08-29 2015-02-28 International Automotive Components Group North America, Inc. Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof
CN105848722B (zh) * 2013-10-02 2021-09-03 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
ES2829913T3 (es) * 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
CA3107872A1 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
WO2017087800A1 (en) 2015-11-19 2017-05-26 Abbvie Stemcentrx Llc Novel anti-emr2 antibodies and methods of use
BR112018010360A2 (pt) 2015-11-24 2018-12-04 Annexon Inc fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
EP3408279A1 (en) 2016-01-27 2018-12-05 CSL Behring Lengnau AG Recombinant igg fc multimers
WO2017196960A1 (en) 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
WO2018107109A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
AU2018236267A1 (en) 2017-03-14 2019-09-26 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
CA3119655A1 (en) 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use

Also Published As

Publication number Publication date
US11591386B2 (en) 2023-02-28
CN113260375A (zh) 2021-08-13
WO2020121282A1 (en) 2020-06-18
EP4375297A2 (en) 2024-05-29
JP2022512223A (ja) 2022-02-02
KR20210100688A (ko) 2021-08-17
EP3893924A1 (en) 2021-10-20
US11161900B2 (en) 2021-11-02
US11708403B2 (en) 2023-07-25
US20200239554A1 (en) 2020-07-30
AU2019397614A1 (en) 2021-06-03
BR112021011107A2 (pt) 2021-12-14
US20240002484A1 (en) 2024-01-04
SG11202105195PA (en) 2021-06-29
US20220267424A1 (en) 2022-08-25
JP7110491B2 (ja) 2022-08-01
CA3119655A1 (en) 2020-06-18
IL283916A (en) 2021-07-29
JP2022160479A (ja) 2022-10-19
MX2021006864A (es) 2021-07-02
AU2019397614B2 (en) 2022-09-15
AU2022287637A1 (en) 2023-02-02
US20220119509A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
EA202091710A1 (ru) Антитела против cd73 и способы их применения
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
EA202090227A1 (ru) Анти-lag-3 антитело, обладающее повышенной стабильностью
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202092735A1 (ru) Антагонизирующее cd73 антитело
ZA202100676B (en) Anti-tigit antibody and uses thereof
EA202090275A2 (ru) Антитела против с5 с улучшенными фармакокинетическими характеристиками
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201892774A1 (ru) Антитела
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
JO3623B1 (ar) البروتينات المرتبطة بمولد المستضاد st2
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
EA201690503A1 (ru) Антитела
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
WO2015184403A3 (en) Anti-epidermal growth factor receptor (egfr) antibodies
ZA202201464B (en) Anti-tigit antibodies and application thereof
EA202191658A1 (ru) Антитела против фактора c2b комплемента человека и способы применения
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
WO2016063026A3 (en) Selective nav protein binders